KOL

Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024

Retrieved on: 
Tuesday, February 20, 2024
Therapy, Liver, SAN, University, Safety, MASH, Patient, NASH, KOL

SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will host a virtual Key Opinion Leader (KOL) event featuring Stephen Harrison, MD, Visiting Professor in the Radcliffe Department of Medicine at the University of Oxford, UK, to discuss the unmet need and current treatment landscape for patients with metabolic dysfunction-associated steatohepatitis (MASH, previously known as NASH) and Aligos’ Phase 2a HERALD study, intended to evaluate the safety and efficacy of ALG-055009, on Thursday, March 7, 2024 at 4:00 PM ET.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will host a virtual Key Opinion Leader (KOL) event featuring Stephen Harrison, MD, Visiting Professor in the Radcliffe Department of Medicine at the University of Oxford, UK, to discuss the unmet need and current treatment landscape for patients with metabolic dysfunction-associated steatohepatitis (MASH, previously known as NASH) and Aligos’ Phase 2a HERALD study, intended to evaluate the safety and efficacy of ALG-055009, on Thursday, March 7, 2024 at 4:00 PM ET.
  • To register, click here.
  • During the event, Dr. Harrison will also discuss some of the key differentiating features of ALG-055009, a next generation thyroid hormone beta agonist.
  • A live question and answer will follow the formal presentation.

Anti-Integrin Agents Market Research Report 2024: In-Depth Analysis on Size, Target Population, Competitive Landscape and Forecast to 2034 - Focus on 7 Major Markets - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 5, 2024
Health, Pharmaceutical, Therapy, Competitive landscape, News, SWOT, EU4, Internet, Accessibility, Patient, Research report, KOL, Pharmaceutical industry

The "Anti-integrin Agents Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Anti-integrin Agents Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.
  • This detailed publication offers critical insights into the current and future landscape of Anti-integrin Agents, covering the gamut from existing treatments to emerging therapies.
  • The report delves into the competitive landscape of individual therapies, the patient pool eligible for Anti-integrin therapy, and also examines the market share of these treatments.
  • Strategic Market Forecast: Forecasted market trends propelling the Anti-integrin Agents market will equip stakeholders with key knowledge, aiding in strategic decision-making.

China's Liquor Circulation Giant Jiuxian Group: GMV May Reach 10 Billion, Leading the Reform of China's Liquor Industry

Retrieved on: 
Tuesday, February 27, 2024
Retail, Wine & Spirits, Marketing, Internet, Advertising, Social media, KOL, GMV, Multimedia

View the full release here: https://www.businesswire.com/news/home/20240226212765/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240226212765/en/
    Jiuxian Group won the honor of "the first brand value of Chinese liquor circulation" in Huazun Cup for 8 consecutive years.
  • Behind this honor is Jiuxian Group's ultimate pursuit of quality, keen insight into market trends and accurate grasp of consumer demand.
  • Through the livestreaming, Jiuxian Group not only provided consumers with a more intuitive and vivid shopping experience, but also successfully won many leading livestreamers such as "Jiuxian Lafeige", "Jiuxian Liangge" and "Jiuxian Daliang".
  • In addition, in terms of marketing, Jiuxian Group has also made massive innovations and took the initiative to try.

PayerPro360 - Empowering Pharma/Biotech with Robust Payer Insights

Retrieved on: 
Tuesday, March 5, 2024
Knowledge, International, Research, Drug development, Charity (practice), Clutch (eggs), KOL, Health care

HARTFORD, Conn., March 5, 2024 /PRNewswire/ -- Thelansis Knowledge Partners, specialized in pharmaceutical and biopharmaceutical business research and consulting Company, launched PayerPro360 To empower Pharma/Biotech with Robust Payer Insights.

Key Points: 
  • HARTFORD, Conn., March 5, 2024 /PRNewswire/ -- Thelansis Knowledge Partners, specialized in pharmaceutical and biopharmaceutical business research and consulting Company, launched PayerPro360 To empower Pharma/Biotech with Robust Payer Insights.
  • PayerPro360 by Thelansis - Empowering Pharma/Biotech with Robust Payer Insights.
  • PayerPro360 is an innovative and user-friendly AI-based platform developed by Thelansis Knowledge Partners, designed to revolutionize Payer Research.
  • Payer market research and insights generation are integral to pharma decision-making during drug development, premarket launch strategy, and post-marketing activities.

Psychedelics set to be the revolutionary treatments in pscyhiatry- Thelansis Knowledge Partners

Retrieved on: 
Thursday, February 22, 2024
Knowledge, DSM-IV codes, Esketamine, TRD, Major depressive disorder, Drug development, TAS, USFDA, Psilocybin, MDMA, Psychiatry, CNS, Patient, Acute stress disorder, PTSD, Polypharmacy, Psychotherapy, MDD, KOL, Research, Central nervous system disease, Pharmaceutical industry

Availability of psychedelic(s) with few administrations in a year and offering high remission rate could change the treatment pathway for these patients."

Key Points: 
  • Availability of psychedelic(s) with few administrations in a year and offering high remission rate could change the treatment pathway for these patients."
  • According to an interviewed U.S.-based neurologist by Thelansis – "We desperately need disease-modifying treatments for many neurodegenerative conditions.
  • As psychedelics would be beneficial for treatment-nonresponders or severe patients, the commercial opportunities are multiple for in-pipeline psychedelic therapies.
  • What is the probable opportunity for Psychedelics (e.g., psilocybin, MDMA) to address the unmet needs of other TAs?

Psychedelics set to be the revolutionary treatments in pscyhiatry - Thelansis Knowledge Partners

Retrieved on: 
Thursday, February 22, 2024
Knowledge, DSM-IV codes, Esketamine, TRD, Major depressive disorder, Drug development, TAS, USFDA, Psilocybin, MDMA, Psychiatry, CNS, Patient, Acute stress disorder, PTSD, Polypharmacy, Psychotherapy, MDD, KOL, Research, Central nervous system disease, Pharmaceutical industry

Availability of psychedelic(s) with few administrations in a year and offering high remission rate could change the treatment pathway for these patients."

Key Points: 
  • Availability of psychedelic(s) with few administrations in a year and offering high remission rate could change the treatment pathway for these patients."
  • According to an interviewed U.S.-based neurologist by Thelansis – "We desperately need disease-modifying treatments for many neurodegenerative conditions.
  • As psychedelics would be beneficial for treatment-nonresponders or severe patients, the commercial opportunities are multiple for in-pipeline psychedelic therapies.
  • What is the probable opportunity for Psychedelics (e.g., psilocybin, MDMA) to address the unmet needs of other TAs?

Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight

Retrieved on: 
Wednesday, February 14, 2024
PD, Newcastle University, Analyst, Research, University Medical Center, Internet, PI, Synucleinopathy, Biomarker, Therapy, Genetics, Task force, Columbia University, KOL, Symptomatic treatment, Pharmaceutical industry

“Beyond Symptomatic Treatment of Parkinson’s Disease: Gain Therapeutics R&D Update with KOL & Analyst Insights 2024”

Key Points: 
  • “Beyond Symptomatic Treatment of Parkinson’s Disease: Gain Therapeutics R&D Update with KOL & Analyst Insights 2024”
    GBA-associated Parkinson’s Disease & other Synucleinopathies: current unmet medical needs and needed therapies.
  • Discussion of recent in vivo data for GT-02287 as a best-in-class small molecule, for the treatment of GBA-Parkinson’s Disease and other neurodegenerative diseases.
  • His research interests are focused on the understanding of the molecular mechanisms of neurodegenerative diseases such as Parkinson’s, Huntington’s, and Alzheimer’s disease.
  • He is Chair of the Task Force on the Biological Definition of Parkinson’s Disease of Internation Parkinson and Movement Disorder Society.

Tonix Pharmaceuticals Hosted KOL Webinar on Positive Phase 3 Fibromyalgia Trial for Tonmya™, Plans to File NDA for FDA Approval in Second Half of 2024

Retrieved on: 
Wednesday, February 14, 2024
Fibromyalgia, Tonix Pharmaceuticals, FDA, Pain, Food, Sleep, Behavioral neuroscience, Hope, Hydrogen chloride, University, Fatigue, Patient, University of Cincinnati, University of Michigan, Psychiatry, Tablet, NDA, KOL, Pharmaceutical industry

CHATHAM, N.J., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, held a key opinion leader (KOL) webinar to discuss the positive Phase 3 data of Tonmya™ (also known as TNX-102 SL, cyclobenzaprine HCl sublingual tablets) for the management of fibromyalgia, and the path to file for FDA approval in the second half of 2024. The webinar was held on January 31, 2024 and hosted by Alliance Global Partners (A.G.P.).

Key Points: 
  • The webinar was held on January 31, 2024 and hosted by Alliance Global Partners (A.G.P.).
  • As previously announced, Tonix’s second positive Phase 3 study, RESILIENT, met its pre-specified primary endpoint, significantly reducing daily pain compared to placebo (p=0.00005) in participants with fibromyalgia.
  • Tonix plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the second half of 2024 for Tonmya™ for the management of fibromyalgia.
  • “We are now an important step closer to bringing a new, first-line treatment to fibromyalgia patients that offers broad symptom relief and favorable tolerability for chronic use and adherence.”

TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR

Retrieved on: 
Wednesday, February 14, 2024
Translational medicine, Senior, AML, ALL, Medicine, Syndrome, HCT, Risk, Society, MDS, Therapy, Patient, Acute leukemia, TCR, Transplant, Acute myeloid leukemia, KOL, Cancer

WALTHAM, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the Company will host a virtual key opinion leader (KOL) event to discuss updated results from its Phase 1 heme malignancies study and highlights from its oral presentation at the 2024 Tandem Meetings: Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT®) and the Center for International Blood and Marrow Transplant Research (CIBMTR®) on Monday, February 26, 2024, at 8:00 a.m. ET.

Key Points: 
  • ET.
  • The event will provide an in-depth review of the oral presentation related to TScan’s ongoing Phase 1 multi-arm clinical trial evaluating TSC-100 and TSC-101, which are designed to treat residual disease and prevent relapse following hematopoietic cell transplantation (HCT) in patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or acute lymphocytic leukemia (ALL) ( NCT05473910 ).
  • The Company will also discuss the potential implications of initial data from a large prospective clinical trial assessing the relationship between donor chimerism and risk of relapse.
  • Shrikanta Chattopadhyay, M.D., M.M.Sc., Senior Vice President of Medical and Translational Medicine, TScan Therapeutics

The Concinnity Company Announces a Major Upgrade to its eClinical Trial Management Software

Retrieved on: 
Thursday, February 8, 2024
Cloud, KOL, Ecosystem, Quality of life, ChromeOS, Documentation, Clinical trial, Adobe, DocuSign, Medical imaging

NASHVILLE, Tenn., Feb. 8, 2024 /PRNewswire/ -- The Concinnity Company has announced the release of Cloud ConcinnityⓇ 3.0.0.

Key Points: 
  • NASHVILLE, Tenn., Feb. 8, 2024 /PRNewswire/ -- The Concinnity Company has announced the release of Cloud ConcinnityⓇ 3.0.0.
  • Cloud Concinnity is an integrated software platform for clinical trial oversight.
  • Concinnity was recently named a Top Ten eClinical Trial Management Solution Provider.
  • Cloud Concinnity v3.0.0 is 21 CFR Part 11 compliant with the current Part 11 industry standards.